Harder J A, Kelly M E
School of Pharmacy, University of Bradford, West Yorkshire, UK.
Pharmacol Biochem Behav. 1997 Apr;56(4):657-61. doi: 10.1016/s0091-3057(96)00413-3.
A combined treatment of a 3-day regimen of pCPA and low-dose scopolamine produced a significant deficit in the acquisition of a water maze task, which has been suggested as a model for the cognitive deficits of Alzheimer's disease. The putative cognition enhancers oxotremorine, captopril, ondansetron, and tacrine were used in attempts to alleviate the water maze impairment. The effects of oxotremorine were difficult to determine due to nonspecific motor effects causing alterations in swimming speed. No evidence for cognition-enhancing properties of captopril was found. Ondansetron showed a cognition-enhancing effect on one of 4 days, but only at a relatively high dose (1 mg/kg i.p.). Tacrine, however, alleviated the pCPA + scopolamine-induced cognitive deficit. This study may thus provide evidence for the usefulness of tacrine in treating spatial deficits in dementia.
对氯苯丙氨酸（pCPA）三日疗法与低剂量东莨菪碱的联合治疗导致水迷宫任务习得出现显著缺陷，水迷宫任务已被视作阿尔茨海默病认知缺陷的模型。使用了假定的认知增强剂氧化震颤素、卡托普利、昂丹司琼和他克林，试图减轻水迷宫损伤。由于非特异性运动效应导致游泳速度改变，氧化震颤素的效果难以确定。未发现卡托普利具有认知增强特性的证据。昂丹司琼仅在4天中的1天显示出认知增强作用，但仅在相对高剂量（腹腔注射1毫克/千克）时出现。然而，他克林减轻了对氯苯丙氨酸+东莨菪碱诱导的认知缺陷。因此，本研究可能为他克林治疗痴呆症空间缺陷的有效性提供证据。
